Leading biotech and pharmaceutical companies on the Fortune China 500 ranking 2023

According to the Fortune China 500 ranking in 2023, China Resources Pharmaceutical Group ranked first among all Chinese biotech and pharmaceutical companies, with an annual revenue of about 552 billion yuan in 2022. Shanghai Pharmaceuticals was the second placeholder with almost 232 billion yuan in annual revenue, followed by CR Pharmaceutical Group with a small margin. The ranking is based on total revenue in 2022 and was released in July 2023. Brief overview of the industry China was one of the pioneers of the medical and healthcare industry in the Asia-Pacific region, especially in the fields of pharmaceuticals and biotechnology. The Chinese pharmaceuticals industry had registered promising growth in recent years, mainly due to favourable market regulation policies which had broadened the market access of patented drugs. The leading pharmaceutical manufacturer, Shanghai Pharmaceuticals, registered significant growth in revenue in the last decade. Its rise has been aided by the faster approval process of new drugs, overseas market expansion and a collective industry movement towards innovative products. The role of traditional Chinese medicine (TCM) With over 3000 years of history, the Chinese tradition of using animal and herbal extracts for treatment is gaining gradual popularity among its western counterparts. Guangzhou Baiyunshan Pharmaceuticals, Yunnan Baiyao Group, and Beijing Tong Reng Tang are the prominent TCM manufacturers with considerable gross profits. The traditional Chinese medicine industry has received progressive assistance from government initiatives to improve industry standards and efficiency in the production of traditional medicine. In the COVID-19 pandemic, TCM also played an important role as a measure to boost public immunity.

依据2023年《财富》中国500强排名，中国医药集团在所有中国生物科技与制药企业中位居首位，2022年度营收约为5520亿元人民币。上海医药紧随其后，以2320亿元的年度营收占据第二位，中国医药集团紧随其后，差距微乎其微。该排名基于2022年度的总营收，并于2023年7月发布。行业概况方面，中国乃亚太地区医疗与健康产业的先驱，尤其在制药与生物技术领域表现突出。近年来，中国制药产业呈现可喜的增长势头，主要得益于有利的市场监管政策，这些政策扩大了专利药品的市场准入。领先的制药制造商上海医药在过去十年中营收显著增长。其崛起得益于新药审批流程的加速、海外市场的拓展以及整个行业向创新产品的集体转型。传统中医（TCM）的作用拥有超过3000年历史的中国传统动物与草药提取物治疗之术，逐渐在国际上获得认可。广州白云山制药、云南白药集团、北京同仁堂等均为盈利丰厚的中医制造企业。传统中医产业亦受益于政府举措，以提升行业标准与提高传统药生产效率。在COVID-19大流行期间，TCM亦发挥了重要作用，作为提升公众免疫力的措施。